ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes that is headquartered in San Diego, California and was founded in 1999 by Paul Laikind.
Timeline
The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.
Funding Rounds
SBIR/STTR Awards
Patents
Further Resources
$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes
Beyondtype1
Web
Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients
ViaCyte, Inc.
Web
CRISPR Therapeutics and Viacyte launch diabetes partnership
BIOCOM AG
Web
ViaCyte encapsulated islet cells show survival success in type 1 diabetes trial
Benedict Jephcote
Web
ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes
ViaCyte, Inc.
Web